BAP1-TPDS increases susceptibility to various benign and malignant tumors, including BAP1-inactivated melanocytic tumors (BIMTs), uveal melanoma (UM), malignant mesothelioma (MMe), cutaneous melanoma (CM), and renal cell carcinoma (RCC).2 This evidence concerns the gene BAP1 and cutaneous mastocytosis.